Hana Acquires Inex Marqibo; New Development Focus Is Adult & Elderly ALL
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryHana Biosciences initially will develop Marqibo for use in acute lymphoblastic leukemia following acquisition of the sphingosomal vincristine formulation from Inex
You may also be interested in...
Talon is preparing to launch the leukemia drug on its own in the first quarter of 2013 but remains in talks with potential strategic partners. The company agreed to monitor whether clinical practices experience safety or technical problems while following the 26-step process for preparing the drug for administration.